Product Description:

REKOVELLE® (follitropin delta injection), the first recombinant FSH (rFollicular Stimulating Hormone) for controlled ovarian stimulation derived from a human cell line, is used in women undergoing assisted reproductive technologies (ART) such as in vitro fertilization (IVF).

REKOVELLE® is the first gonadotropin to use an evidence-based, personalized dosing algorithm based on a woman’s anti-Müllerian hormone (AMH) level and body weight to achieve a predictable ovarian response. This is particularly valuable since ovarian response to stimulation varies considerably from woman to woman, and unexpected extreme responses have implications on efficacy and safety.